Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial
…, H Honda, RA Fowler, JS Lazar, G Shi… - The Lancet …, 2021 - thelancet.com
Background Elevated proinflammatory cytokines are associated with greater COVID-19 severity.
We aimed to assess safety and efficacy of sarilumab, an interleukin-6 receptor inhibitor, …
We aimed to assess safety and efficacy of sarilumab, an interleukin-6 receptor inhibitor, …
[HTML][HTML] Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials
…, GD Yancopoulos, DM Weinreich, S Wang, G Shi… - Nature medicine, 2023 - nature.com
Prurigo nodularis (PN) is a chronic inflammatory skin disease with intensely pruritic nodules.
The LIBERTY-PN PRIME and PRIME2 phase 3 trials enrolled adults with PN with ≥20 …
The LIBERTY-PN PRIME and PRIME2 phase 3 trials enrolled adults with PN with ≥20 …
Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia
…, MN Vissers, MD Trip, C Gagné, G Shi… - Journal of the American …, 2008 - jacc.org
Objectives : The study evaluated the efficacy and safety of long-term coadministration of
ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia (…
ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia (…
Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta …
J Chen, Y Ye, H Sun, G Shi - Cancer chemotherapy and pharmacology, 2013 - Springer
Purpose To comparatively evaluate whether metastatic colorectal cancer (mCRC) patients
with KRAS codon 13 mutations (codon 13 muts) can benefit from anti-EGFR treatment. …
with KRAS codon 13 mutations (codon 13 muts) can benefit from anti-EGFR treatment. …
XRCC1 Arg399Gln and clinical outcome of platinum-based treatment for advanced non-small cell lung cancer: a meta-analysis in 17 studies
J Chen, Q Zhao, G Shi, L Wang - Journal of Zhejiang University SCIENCE …, 2012 - Springer
Objective XRCC1 polymorphism is a research hotpot in individual treatment for non-small
cell lung cancer (NSCLC). To obtain the association between XRCC1 polymorphism and …
cell lung cancer (NSCLC). To obtain the association between XRCC1 polymorphism and …
Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial
FX Lescure, H Honda, RA Fowler, JS Lazar, G Shi… - MedRxiv, 2021 - medrxiv.org
Background Elevated proinflammatory cytokines have been associated with 2019 coronavirus
disease (COVID-19) severity. We assessed efficacy and safety of sarilumab, an interleukin…
disease (COVID-19) severity. We assessed efficacy and safety of sarilumab, an interleukin…
[HTML][HTML] Chemosensitivity of radioresistant cells in the multicellular spheroids of A549 lung adenocarcinoma
D Shi, G Shi, G Huang, J Zhang, E Lartigau - Journal of Experimental & …, 2009 - Springer
Background The relapse of cancer after radiotherapy is a clinical knotty problem. Previous
studies have demonstrated that the elevation of several factors is likely in some way to lead to …
studies have demonstrated that the elevation of several factors is likely in some way to lead to …
Combination chemotherapy with paclitaxel, cisplatin and fluorouracil for patients with advanced and metastatic gastric or esophagogastric junction adenocarcinoma: a …
…, FC Zhang, XZ Ma, JJ Huang, L Chen, GM Shi… - Chinese Journal of …, 2012 - Springer
Objective To evaluate the efficacy and toxicity of the combination regimen of paclitaxel, cisplatin
and 5-FU (PCF) as first-line or second-line therapy in patients with advanced gastric and …
and 5-FU (PCF) as first-line or second-line therapy in patients with advanced gastric and …
344 Dupilumab significantly improves itch and skin lesions in patients with prurigo nodularis: pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2)
…, E Mortensen, J Maloney, G Shi… - British Journal of …, 2023 - academic.oup.com
Prurigo nodularis (PN), a chronic inflammatory and pruritic skin condition with severely itchy
skin nodules, substantially affects the quality of life and is often inadequately controlled with …
skin nodules, substantially affects the quality of life and is often inadequately controlled with …
510-Dupilumab is efficacious in patients with prurigo nodularis regardless of stable use of topical corticosteroids and topical calcineurin inhibitors: pooled results from …
…, S Ständer, N Mollanazar, G Shi… - British Journal of …, 2024 - academic.oup.com
Introduction Prurigo nodularis (PN) is a chronic inflammatory skin condition characterized
by severely itchy skin nodules, which substantially affects quality of life. Although topical …
by severely itchy skin nodules, which substantially affects quality of life. Although topical …